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Summary Multifocal capillary malformation (CM) is the cardinal feature of patients with
RASA1 mutations. These CMs are ‘red flags’, signalling the possible association with
an arteriovenous malformation (AVM) or an arteriovenous fistula (AVF). We report
an 8-year-old boy who presented with > 20 CMs, who was found to have a novel
mutation in the RASA1 gene. Radiological screening of children with RASA1 muta-
tions is not standardized, and we elected to carry out baseline magnetic resonance
imaging of the brain and spine in our case, which gave normal results. We discuss
the recent literature and our approach in the management of such a case.
Multifocal capillary malformation (CM) is the cardinal
feature of patients with autosomal dominant inherited
RASA1 mutations, and represents a strong phenotypic
marker, present in 97% of mutation carriers.1 These
CMs are ‘red flags’, signalling the possible association
with an arteriovenous malformation (AVM) or arterio-
venous fistula (AVF). Clinical management of asymp-
tomatic children with RASA1 mutations is not
standardized, and we discuss the recent literature and
our approach in the management of such a case.
Report
An 8-year-old boy presented with in excess of 20 CMs,
mainly affecting his limbs and neck. These had been
present since birth, and new lesions continued
developing during childhood. The patient was other-
wise well. On physical examination, the lesions were
seen to be macular and pink to brown in colour, and
some lesions demonstrated a pale halo (Fig. 1a,b).
There was a high suspicion of capillary malformation–
arteriovenous malformation (CM-AVM) syndrome.
Genetic testing confirmed a novel, heterozygous
RASA1 mutation in exon 18, predicted to create a
frameshift and a premature stop codon (c.2467dupG).
Magnetic resonance imaging of the brain and spine
was performed to exclude the presence of an AVM,
and was found to be normal. The proband’s mother
was examined and found to be unaffected. The father
was not available for examination, but was reported to
be unaffected.
Familial occurrence of multiple CMs was first
described in 1949;1 however, it was only in 2002 that
molecular characterization of a subset of these patients
led to the identification of heterozygous mutations in
RASA1.2 To date, > 100 mutations in this gene have
been reported, and no genotype–phenotype correlation
is seen.1,3 Approximately 30% of RASA1 mutation
carriers have a de novo mutation, and the penetrance
is high (96.5%).4
RASA1 (ras p21 protein activator 1) encodes the
protein p120 RasGAP, an important regulator of vas-
cular cellular differentiation and proliferation. The
CMs associated with RASA1 mutations in humans are
different to isolated CMs, and are characterized by a
red/brown colour, random distribution and the pres-
ence of a whitish peripheral halo in a third of the
lesions, suggestive of vascular steal.5 The malforma-
tions may be present at birth, but usually appear in
early childhood, and may increase in number with
age.4 It has been postulated that a somatic ‘second
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hit’ genetic mutation is necessary for the development
of cutaneous lesions, and this could explain the local-
ized nature, progressive development and multifocality
of the lesions. A recently identified loss of the wild-type
allele in CM tissue supports this hypothesis.1
In addition to having CMs, 23% of patients with
RASA1 mutations have fast-flow vascular anomalies:
AVM, AVF or Parkes Weber syndrome (PKWS).2,4,6
AVMs are rare, fast-flow anomalies that can cause
fatal complications such as bleeding, congestive car-
diac failure or neurological deficit. Approximately 10%
of these lesions are located in the brain and spinal
cord.7 The lesions may present at birth but can be
asymptomatic for some years. Previously reported
intracranial arteriovenous lesions in CM-AVM in
patients with RASA1 mutations are typically macrofis-
tulas, usually presenting with neurological signs at
birth or before 1 year of age. The goal of treatment in
cortical AVF in young children, even when asymptom-
atic, is rapid control of the shunt, because of the high
mortality and worse neurocognitive prognosis when
managed conservatively. Walcott et al. studied a group
of RASA1 mutation carriers who were recognized to
be at risk for paediatric pial AVF. These are rare vas-
cular lesions of the CNS, characterized by direct arte-
rial connections to a pial venous channel, which pose
a high risk of haemorrhage.8 Thiex et al. described a
previously undocumented association between RASA1
mutations and fast-flow anomalies in the spine caus-
ing severe sensorimotor defects. In that study, neuro-
logical symptoms became apparent as late as at
23 years of age in one patient.6
The radiological screening of neonates and young
children with a RASA1 mutation has recently been
proposed.7 However, reports of older children
(> 7 years of age) presenting with RASA1 mutations
and CM without radiologically confirmed intracranial
AVM/AVF are limited.9,10 Although Revencu et al.4
reported that most of the intracranial lesions are mac-
rofistulas and cause symptoms in infancy, ascertain-
ment bias cannot be excluded, as their patients may
have had imaging arranged as a result of their signs
and symptoms.13 In addition, prospective studies in
RASA1 mutation carriers to carefully characterize
intracranial or spinal AVMs AVFs have not been per-
formed, making estimation of the true prevalence of
asymptomatic lesions in childhood difficult in this
group.
We suggest that screening using magnetic reso-
nance imaging should be considered in asymptomatic
children to identify subclinical high-flow intracranial
and spinal vascular lesions. The existing gap in
knowledge as to whether these AVMs and AVFs can
progress or develop after such a screening scan
remains an obstacle that prevents informed planning
of further scans in the absence of symptoms. CMs
continue to develop in the skin of these patients in
childhood, however, and this emphasizes the impor-
tance of educating parents to report new neurological
signs early. As further clinical data become available
for these older children carrying RASA1 mutations,
intervals for further screening in the absence of new
neurological signs can be refined. Although this
approach carries the attendant risk of discovering
(a) (b)
Figure 1 (a) A large capillary malforma-
tion with a red–brown appearance and a
surrounding pale halo, seen on the med-
ial aspect of the left leg, which had been
present since birth. The white lesion
within the malformation is a biopsy scar.
(b) Smaller similar lesions on the right
leg; the smallest of these had appeared in
childhood.
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incidental lesions of uncertain significance, it may
make it possible to anticipate cerebral and spinal
haemorrhages, which could have catastrophic conse-
quences if left untreated.
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Learning points
 CM is a cardinal feature of patients with
RASA1 mutations.
 An estimated 10% of patients with RASA1
mutations carry fast-flow vascular anomalies that
affect the brain or spinal cord.
 The majority of these patients present in early
childhood with neurological symptoms; however,
some can present in the second decade of life.
 We propose baseline imaging of the brain and
spinal cord in older, asymptomatic children with
RASA1 mutations to aid early detection and
management of fast-flow lesions.
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